Linezolid-resistant Enterococcus casseliflavus and Enterococcus gallinarum isolated from poultry farms in Kelantan, Malaysia

Aims@#Linezolid has become a decisive therapy in treating infections with vancomycin-resistant Enterococcus (VRE). Currently, the emergence of linezolid-resistant Enterococcus further complicates the therapeutic options and leads to global health threat not only in hospital setting but in the community. The study aimed at antimicrobial pattern of Enterococcus isolated from 6 poultry farms in Kelantan, Malaysia.@*Methodology and results@#Between February and December 2019, 300 broiler cloacal swab sample (Gallus gallus domesticus) were collected and screened for linezolid-resistant enterococci (LRE) using a standard biochemical and antimicrobial susceptibility tests. Among all the samples, 32.3% (n=97/300) grew Enterococcus, 71.1% (n=69/97) of it were identified Enterococcus casseliflavus by molecular identification, whilst remaining isolates 28.9% (n=28/97) were further identified as Enterococcus gallinarum by 16S rRNA sequencing. None of the isolates were found to exhibit high-level resistance to vancomycin. However, 3/97 (3.1%) were exhibit resistance to high-level gentamicin based on Kirby-Bauer disk diffusion test. Whereas 48/97 (49.5%) of isolates were observed to be resistant to ampicillin, 28/97 (28.9%) were resistant to penicillin. Surprisingly, among the two strains isolated, 18.6% (n=18/97) of it were resistant to linezolid. Isolates showed resistance to linezolid by disk diffusion test were verified by VITEK-2 automated system (bioMérieux, USA) with MIC ≥8 µg/mL. All antimicrobial susceptibility test and minimal inhibitory concentration (MIC) results were interpreted according to Clinical and Laboratory Standard Institute (CLSI). @*Conclusion, significance and impact of study@#In conclusion, this study has reported the prevalence of linezolid resistant Enterococcus (LRE) in highly intrinsic antibiotic resistant of E. casseliflavus and E. gallinarum in Malaysia poultry farms, alongside with the truancy of vanA strains. The emergence of LRE strains is an alarming problem to the animal husbandry and healthcare setting worldwide. This could lead to potentially untreatable and life-threatening enterococcal infections. Even more worrying is the spread of LRE to geographical regions where these strains were previously unreported, which may pose a global health threat. Antimicrobial surveillance in poultry husbandry is thus, dimly necessary to prevent wide spread of multidrug-resistant bacteria.

Emergence of optrA-Mediated Linezolid-Nonsusceptible Enterococcus faecalis in a Tertiary Care Hospital

This study investigated resistance mechanisms and epidemiology of emerging linezolid-nonsusceptible Enterococcus faecalis (LNSEF) in a tertiary care hospital. LNSEF isolated from clinical samples were collected from November 2017 to June 2019. The isolates were investigated for linezolid resistance and the associated molecular mechanisms, including mutations of 23S rRNA domain V and acquisition of the cfr or optrA resistance gene. We used pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing for the molecular typing of the isolates. Among 4,318 E. faecalis isolates, 10 (0.23%) were linezolid-nonsusceptible. All LNSEF isolates were optrA-positive and cfr-negative. Of these isolates, five were sequence type (ST) 476, two ST585, one ST16, one ST16-like, and one ST480. Six LNSEF isolates obtained in the first year clustered to three types in the PFGE analysis: two ST476 isolates of type A, two ST585 isolates of type B, and two ST16 or ST16-like isolates of type C. Seven cases were of community-onset and three were hospital acquired, but total of eight were healthcare-associated including five community-onset. None of the patients had a history of linezolid treatment, and in one patient, we detected linezolid-susceptible E. faecalis one month before LNSEF detection. In conclusion, heterogenous clones of optrA-positive LNSEF emerged in the hospital mainly via community-onset.

Molecular epidemiology of coagulase-negative bloodstream isolates: detection of Staphylococcus epidermidis ST2, ST7 and linezolid-resistant ST23

Abstract The mechanisms contributing to persistence of coagulase-negative staphylococci are diverse; to better understanding of their dynamics, the characterization of nosocomial isolates is needed. Our aim was to characterize phenotypic and molecular characteristics of Staphylococcus epidermidis and Staphylococcus haemolyticus human blood isolates from two tertiary care hospitals in Mexico, the Hospital Universitario in Monterrey and the Hospital Civil in Guadalajara. Antimicrobial susceptibility was determined. Biofilm formation was assessed by crystal violet staining. Detection of the ica operon and Staphylococcal Cassette Chromosome mec typing were performed by PCR. Clonal relatedness was determined by Pulsed-fiel gel electrophoresis and Multi locus sequence typing. Methicillin-resistance was 85.5% and 93.2% for S. epidermidis and S. haemolyticus, respectively. Both species showed resistance >70% to norfloxacin, clindamycin, levofloxacin, trimethoprim/sulfamethoxazole, and erythromycin. Three S. epidermidis and two S. haemolyticus isolates were linezolid-resistant (one isolate of each species was cfr+). Most isolates of both species were strong biofilm producers (92.8% of S. epidermidis and 72.9% of S. haemolyticus). The ica operon was amplified in 36 (43.4%) S. epidermidis isolates. SCCmec type IV was found in 47.2% of the S. epidermidis isolates and SCCmec type V in 14.5% of S. haemolyticus isolates. No clonal relatedness was found in either species. Resistance to clindamycin, levofloxacin, erythromycin, oxacillin, and cefoxitin was associated with biofilm production for both species (p < 0.05). A G2576T mutation in 23S rRNA gene was detected in an S. haemolyticus linezolid-resistant isolate. All linezolid-resistant S. epidermidis isolates belonged to ST23; isolate with SCCmec type IV belonged to ST7, and isolate with SCCmec type III belonged to ST2. This is the first report of ST7 in Mexico. There was a high genetic diversity in both species, though both species shared characteristics that may contibute to virulence.

Detection of the classical G2576U mutation in linezolid resistant Staphylococcus aureus along with isolation of linezolid resistant Enterococcus faecium from a patient on short-term linezolid therapy: First report from India.

Purpose: Linezolid is an effective drug against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). We describe the emergence of linezolid resistance in MRSA and VRE from India. Material and Methods: One MRSA and two VRE strains were isolated from a patient on linezolid therapy of one week duration. All three isolates were resistant to linezolid with minimal inhibitory concentrations (MIC) ≥4 mg/L. The 746-bp region fl anking the possible G2576U mutation on the corresponding DNA from the 23S rRNA was amplifi ed by polymerase chain reaction (PCR) and amplicons were sequenced for all the three isolates. Conjugation experiments using the linezolid resistant MRSA (LRMRSA) and linezolid resistant VRE (LRVRE) isolates as donors and wild strains of corresponding genera as recipients were performed. Results: The MRSA isolate had the classical G2576U mutation. High quality value scores in the sequencing software validated the mutation. Conjugation studies did not indicate presence of transferable resistance for linezolid. Sequencing did not indicate presence of any mutation in the two LRVRE isolates. Conclusions: This is the fi rst report from India citing resistance in Staphylococcus and Enterococcus against Linezolid.

Enterococci: A journey of a successful pathogen.

Introduction: A dynamic homeostasis is maintained between the host and native bacteria of the gastrointestinal tract in humans, but migration of bacteria from the gut to other organs can lead to disease or death. Enterococci, traditionally viewed as commensal bacteria are now acknowledged to be organisms capable of causing life-threatening infections in humans, especially in the nosocomial environment. The existence of Enterococci in such a dual role is facilitated by its intrinsic and acquired resistance to virtually all antibiotics currently in use. Objective: The present pilot study was taken up to compare the multidrug resistance prevalence in commensal Enterococci and pathogenic Enterococci. Material and methods: A total of 50 commensal Enterococci isolated from stool samples and 50 clinical samples yielding Enterococci were taken for the study. Antibiotic susceptibility testing was done using Kirby Bauer’s disk diffusion method. Minimum inhibitory concentration of Vancomycin was tested by using E- strip. Results: Among 50 commensal Enterococci, majority showed resistance to Ampicillin 50 (100%), Erythromycin 38 (76%), Clindamycin 30 (60%), higher level of resistance to high level Gentamycin 14 (28%), Linezolid 6 (12%), vancomycin 3 (6%). 23 (46%) isolates showed multi drug resistance (resistance to ≥ 3 categories of antibiotics). Among 50 clinical isolates, majority showed resistance to Ampicillin 50 (100%), Erythromycin 38 (76%), Clindamycin 30 (60%), higher level of resistance to high level Gentamycin 14 (28%), Linezolid 6 (12%), vancomycin 3 (6%). 23 (46%) isolates showed multi drug resistance (resistance to ≥ 3 categories of antibiotics). Among 50 clinical isolates, majority showed resistance to Ampicillin 50 (100%), Clindamycin 46 (92%), Tetracycline 46 (92%), Erythromycin 41 (82%), Linezolid resistance was seen in 8 (16%) and Vancomycin resistance in 5(10%) clinical isolate. 48(96%) showed multi drug resistance. Conclusion: Boundary line between pathogenic and commensal Enterococci is blurred due to exchange of resistant traits. Regular screening of enterococcal isolates for resistance detection should be implemented. It is very important to consider infection control measures, screening of health care workers, surveillance cultures which can control spread of multidrug resistant Enterococci.

Screening, isolation, taxonomy and fermentation of an antibiotic producer Streptomyces xinghaiensis from soil capable of acting against linezolid resistant strains.

Linezolid resistant cultures are emerging in hospitals. In the present study 3 soil actinomycetes were isolated in a screening programme having potential to produce antibiotic against linezolid resistant cases. One culture was coded as RK-46 and further studied. The micromorphology, biochemical tests and 16S ribosomal DNA gene sequence analysis were conducted to know the identity of the culture and was found as a strain of Streptomyces xinghaiensis. The culture produced antibiotic active against five clinical resistant strains. The antibiotic production was tested by cultivating in eleven different media. The fermentation profile was studied in YEME medium supplemented with calcium carbonate. The maximum activity was noticed at 72 h. Antibiotic activity was extracted into ethyl acetate and was subjected to activity guided purification by column chromatography, TLC and HPLC methods. The pure compound was eluted with retention time of 6.8 min and subjected to 1H, 13C NMR and Mass spectral analysis. The acquired data was compared with that in natural products data base, and was found to be a known antibiotic, reductiomycin. The purified compound showed activity against 5 linezolid resistant cultures and on Mycobacterium tuberculosis. This compound is also showing mild anti cancer activity and is biologically permeable as per Lipinksi’s rule.

Sepsis due to linezolid resistant Staphylococcus cohnii and Staphylococcus kloosii: First reports of linezolid resistance in coagulase negative staphylococci from India.

Linezolid, a viable alternative to vancomycin against methicillin resistant staphylococcal isolates, has been in use for a decade around the globe. However, resistance against staphylococci remains extremely rare and unreported from most of the Asian countries. Herein, we report two cases of linezolid resistant, coagulase negative staphylococcal sepsis for the first time from India. The first case was an 18-year-old burn patient, who, after a major graft surgery, landed in sepsis, and linezolid resistant Staphylococcus cohnii with an minimum inhibitory concentration (MIC) of >256 μg/ml by both broth microdilution and Etest, was isolated from multiple blood cultures. The second patient was a 60-year-old male with an intracranial bleed and sepsis, from whose blood cultures, linezolid resistant Staphylococcus kloosii was repeatedly isolated. Linezolid MIC was >32 μg/ml by broth microdilution and >16 μg/ml by Etest.